Company news

Intellia Therapeutics, Inc. news in 2023

Intellia Therapeutics, Inc.'s news releases, calls and decks from 2023, newest first.

View company

Intellia Therapeutics Receives European Union Orphan Drug Designation for NTLA-2002, an Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary Angioedema

November 13, 2023

Intellia Therapeutics Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress

November 8, 2023

Intellia Presents New Interim Data from the Ongoing Phase 1 Study of NTLA-2001 at the 4th International ATTR Amyloidosis Meeting

November 1, 2023

Intellia Therapeutics to Present Updated Data from Ongoing Phase 1 Study of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis and Hold Conference Call to Discuss Third Quarter 2023 Earnings in November

October 25, 2023

Intellia Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application to Initiate a Pivotal Phase 3 Trial of NTLA-2001 for the Treatment of Transthyretin (ATTR) Amyloidosis with Cardiomyopathy

October 17, 2023

Intellia Therapeutics Receives Priority Medicines (PRIME) Designation From the European Medicines Agency for NTLA-2002, an Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary Angioedema

October 12, 2023

Regeneron and Intellia Announce Expanded Research Collaboration to Develop CRISPR-Based Therapies for the Treatment of Neurological and Muscular Diseases

October 2, 2023

Intellia Therapeutics Announces Second Quarter 2023 Financial Results and Highlights Recent Company Progress

August 2, 2023

Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2023 Earnings and Company Updates

July 26, 2023

Intellia Therapeutics Announces New Positive Clinical Data from Phase 1 Study of NTLA-2002, an Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary Angioedema (HAE)

June 10, 2023

Intellia Therapeutics Announces Retirement of Jean-François Formela, M.D. From its Board of Directors

June 4, 2023

Intellia Therapeutics to Present Updated Interim Data from Ongoing Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the EAACI Hybrid Congress 2023

May 30, 2023

Intellia Therapeutics Announces First Quarter 2023 Financial Results and Highlights Recent Company Progress

May 3, 2023

Intellia Therapeutics Releases 2023 Corporate Responsibility Report Highlighting the Advancement of its Environmental, Social & Governance (ESG) Priorities

April 30, 2023

Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2023 Earnings and Company Updates

April 26, 2023

Intellia Therapeutics Names Bill Chase to its Board of Directors

April 16, 2023

Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to NTLA-2002 for the Treatment of Hereditary Angioedema

March 20, 2023

Intellia Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for NTLA-2002, an In Vivo CRISPR-Based Investigational Therapy for the Treatment of Hereditary Angioedema (HAE)

March 1, 2023

Intellia Therapeutics Announces Fourth Quarter and Full-Year 2022 Financial Results and Highlights Recent Company Progress

February 22, 2023

Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2022 Earnings and Company Updates

February 15, 2023

Intellia Therapeutics Awarded Innovation Passport in the United Kingdom for NTLA-2002, an Investigational Genome Editing Treatment for Hereditary Angioedema

January 10, 2023

Intellia Therapeutics Highlights Strategic Priorities and Anticipated 2023 Key Milestones

January 4, 2023

Calls in 2023

Decks in 2023